Diasorin S.p.a. · MIL:DIA
Diasorin — Jefferies London Healthcare Conference 2024
18 slides from Diasorin's conference presentation, Nov 20, 2024
Slide 1: Jefferies London Healthcare Conference
JEFFERIES LONDON HEALTHCARE CONFERENCE Piergiorgio Pedron, CFO London, UK - November 20th, 2024
Slide 2: Disclaimer
Disclaimer In General. This disclaimer applies to this presentation and any oral comments of any person presenting it. This document, taken together with any such oral comments, is referred to herein as the “Presentation”. This Presentation has been prepared by Diasorin S.p.A. (“Diasorin” or the “Co
Slide 3: Forward-looking statements
Forward-looking statements This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which Diasorin operates and the beliefs and assumptions of the management of Diasorin. In addition, the management of Dias
Slide 4: World leader in the Diagnostic market
• World leader in the Diagnostic market, with a B2B unique offering in the Life Science business • Listed on the Italian Stock Exchange since 2007 and included in the FTSE MIB Index In Vitro Diagnostic (~ €60 billions market size) Life Science Immunodiagnostics Molecular Diagnostics Licensed Technol
Slide 5: Diasorin worldwide
Diasorin worldwide NORTH AMERICA ~50% of Group Revenues NORTH AMERICA EUROPE USA Italy EUROPE Austin Madison Saluggia Chicago Stillwater Bresso Cypress ~35% of Group Revenues Germany Dietzenbach ASIA China Canada UK Toronto Baoshan REST OF WORLD Dartford ~15% of Group Revenues LEGEND Direct presence
Slide 6: Immunodiagnostics
IMMUNODIAGNOSTICS 6) Diasorin
Slide 7: Immunodiagnostic solutions
Immunodiagnostic solutions Immunodiagnostic market: ~ €14 billions Calibrators Diluent Customers: hospitals Magnetic particles Conjugate and private diagnostic labs Reagent rental model Closed System >90% Recurring consumables revenues LIAISON® XS LIAISON® XL LIAISON® XXL* LIAISON® XL LAS Instrument
Slide 8: Unique menu of specialties
Unique menu of specialties «We have the broadest immunoassay menu available on the market» 84 Diasorin Immunoassay tests 63 46 Tests of the main competitor within the area 32 Differentiating & High-Volume Specialties High-routine tests 8 Diasorin’s presentation at Jefferies London Healthcare Confere
Slide 9: Diasorin 3.0: new programs supporting the specialist positioning
Diasorin 3.0: new programs supporting the specialist positioning MeMed BV QuantiFERON® TB • Algorithm-based diagnostic test differentiating between • Golden standard solution for Latent Tubercolosis (TB) testing Bacterial vs Viral infections • WHO estimates 25% of population is affected by TB • Clin
Slide 10: Molecular Diagnostics
MOLECULAR DIAGNOSTICS )y Diasorin
Slide 11: Full Spectrum Solution
Full Spectrum Solution Molecular diagnostic market: ~ €5 billions Point-of-care Single-low Plex Multiplex Transversal expansion Transversal expansion Menu expansion in point-of-care in syndromic OUT OF SCOPE LIAISON® MDX / LIAISON® MDX Plus* * * DECENTRALIZED SETTING LOW VOLUME HIGH VOLUME * To be l
Slide 12: LIAISON PLEX
LIAISON PLEX® PLEX Select 7 most prevalent targets Select additional 6 targets Select additional 6 targets 10% negative 0.5% negative (instant reflex) (instant reflex) $ $$ $$$ COMPETITION Run full panel (all targets) Flex Testing 85-95% of positive are solved by testing Sample-to-answer workflow 7
Slide 13: Licensed Technologies
LICENSED TECHNOLOGIES 6) Diasorin
Slide 14: Licensed Technologies (LTG)
Licensed Technologies (LTG) BEADS SELLING BEADS AND INSTRUMENTS TO PARTNERS TO CREATE THEIR IVD OR RUO ~1/3 of LTG Revenues TESTS INSTRUMENTS ~1/3 of LTG Revenues ROYALTIES ~1/3 of LTG Revenues DIAGNOSTICS LIFE SCIENCE BIOPHARMA Diagnostic kits Academic research Biopharma discovery Transplant Autoim
Slide 15: Financials
FINANCIALS 6) Diasorin
Slide 16: Guidance @CER 2023
Guidance @CER 2023* EBITDA margin EBITDA margin EBITDA margin ~ 33% ~ 33% 36% / 37% Complete High Single Digit to deleverage Low Double Digit increase by 2027 (CAGR) Ex Covid: ~ +7% Covid: ~ 30 €/mln 1,148 €/mln Covid Base Business 2023 2024 2027 *In order to allow comparability across years, all fi
Slide 17: Key Takeaway Messages
Key Takeaway Messages DIVERSIFIED PORTFOLIO U.S. FOCUS RECURRING AND AND CUSTOMER BASE PREDICTABLE REVENUES 15% 15% 10% 20% 50% 65% 35% 90% Licensed Technologies Rest of the World Recurring Molecular Diagnostics Europe Immunodiagnostics Non Recurring North America All percentages are rounded 17 Dias
Slide 18: Diasorin S.p.A. www.diasorin.com
Diasorin S.p.A. www.diasorin.com
Diasorin — Jefferies London Healthcare Conference 2024 on 6ix